A Pilot, Phase I/II Study of the Amino Acid Leucine in the Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia (LeucineDBA) | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01362595

A Pilot, Phase I/II Study of the Amino Acid Leucine in the Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia (LeucineDBA)
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

Leucine will be provided to participants in the form of a capsule and will be taken three times daily.

Blood hemoglobin levels will be monitored every 3-4 weeks for 9 months.

The entire study will last 12-15 months in length.

Subjects must be two years of age or older and on transfusion for more than six months prior to enrollment.

Status: 
Recruiting
Study Date: 
Fri, 05/20/2011 to Thu, 09/01/2016
Bone Marrow Disease(s): 
aplastic anemia
Intervention: 
Drug: leucine Dosage of leucine will be dependent on body surface area (BSA): leucine 700 mg/m2/dose by mouth three times a day Other Name: leucine, L-leucine